BIRCHBIOMED™

BirchBioMed is a cutting-edge clinical-stage biopharmaceutical company headquartered in Canada. The company is dedicated to pioneering innovative treatments for organ fibrosis, scarring (fibrosis) and associated skin disorders, as well as specific subsets of autoimmune disorders, including Type 1 Diabetes and Alopecia Areata... BirchBioMed is a pioneering clinical-stage biopharmaceutical company focused on developing innovative treatments for diseases with high unmet medical needs like organ fibrosis, scarring, skin disorders, and specific clinical autoimmune conditions like Type 1 Diabetes (T1D). Leveraging groundbreaking technologies licensed from the University of British Columbia, BirchBioMed is committed to transforming patient care. Our advanced therapies are poised to set new standards in medical treatment, pending regulatory approvals. With a mission to save lives and cure severe diseases, BirchBioMed is dedicated to delivering transformative healthcare solutions globally.

Also known as: BirchBioMed™, Inc.